EXCALIBER-Maintenance

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)

What's the purpose of the trial?

The goal of this clinical trial is to learn more about the safety and efficacy of Iberdomide when used as maintenance therapy and to compare its safety and efficacy to Lenalidomide when used as maintenance therapy.

The goal of this clinical trial is to compare the efficacy, survival, safety, tolerability, and effects on quality of life (QoL)of maintenance treatment with iberdomide as compared to maintenance treatment with standard of care (SOC) lenalidomide, as well as determining the optimal iberdomide maintenance dose, in patients with newly diagnosed multiple myeloma (NDMM) that have achieved a partial response (PR) or better following autologous stem cell transplant (ASCT).

Trial status

Accepting patients

Phase
Phase 3
Enrollment
1216
Last Updated
4 weeks ago
Patient Screener

Participating Centers

There are 41 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Iberdomide
  • Lenalidomide

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not currently accepting

Stage 1, Arm A1

Not currently accepting

Stage 1, Arm A2

Not currently accepting

Stage 1, Arm A3

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.